Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 80.4% in July

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 145,807 shares, an increase of 80.4% from the June 30th total of 80,824 shares. Currently, 0.9% of the shares of the stock are sold short. Based on an average trading volume of 139,949 shares, the short-interest ratio is presently 1.0 days.

Institutional Trading of Allarity Therapeutics

A number of hedge funds have recently modified their holdings of ALLR. Geode Capital Management LLC grew its holdings in shares of Allarity Therapeutics by 49.3% during the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after buying an additional 16,729 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Allarity Therapeutics in the 2nd quarter valued at about $27,000. XTX Topco Ltd acquired a new position in shares of Allarity Therapeutics in the 4th quarter valued at about $36,000. Citadel Advisors LLC purchased a new stake in shares of Allarity Therapeutics in the third quarter worth approximately $149,000. Finally, Capital Advisors Inc. OK purchased a new position in Allarity Therapeutics during the fourth quarter valued at approximately $108,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Ascendiant Capital Markets increased their target price on shares of Allarity Therapeutics from $9.75 to $10.25 and gave the company a “buy” rating in a research note on Monday, June 8th. Wall Street Zen upgraded Allarity Therapeutics to a “hold” rating in a research report on Saturday, May 30th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Allarity Therapeutics currently has a consensus rating of “Hold” and an average price target of $10.25.

Allarity Therapeutics Price Performance

Shares of ALLR opened at $1.16 on Thursday. Allarity Therapeutics has a one year low of $0.77 and a one year high of $2.35. The company has a 50-day moving average of $1.39 and a two-hundred day moving average of $1.25. The stock has a market cap of $18.46 million, a price-to-earnings ratio of -1.61 and a beta of 0.53.

Allarity Therapeutics (NASDAQ:ALLR) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.05. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. Analysts anticipate that Allarity Therapeutics will post -0.92 earnings per share for the current year.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.